Revenue
2019
2020
2021
2022
2023
2024
2025
Korsana Biosciences, Inc. (KRSA)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.1M | $2.0M | $0 | $297,000 | $3.9M | $2.3M | $4.5M | N/A |
| Research & development | $959,000 | $286,000 | $1.5M | $6.0M | $37.6M | $56.4M | $95.1M | $87.7M |
| Operating expenses | $7.0M | $5.6M | $13.0M | $18.8M | $59.1M | $83.6M | $129.5M | $115.3M |
| Operating income | −$5.0M | −$3.6M | −$13.0M | −$18.5M | −$55.2M | −$81.3M | −$125.0M | −$115.3M |
| Operating margin | −239.78% | −181.40% | N/A | −6,242.42% | −1,400.18% | −3,539.42% | −2,774.28% | N/A |
| EBITDA | −$5.0M | −$3.6M | −$13.0M | −$18.5M | −$54.7M | −$79.0M | −$122.3M | −$113.7M |
| EBITDA margin | −239.78% | −181.40% | N/A | −6,220.54% | −1,388.20% | −3,439.37% | −2,714.38% | N/A |
| Net income | −$3.5M | −$3.1M | −$5.3M | −$44.1M | −$51.6M | −$77.8M | −$123.0M | −$115.3M |
| Net profit margin | −170.11% | −152.85% | N/A | −14,841.08% | −1,310.17% | −3,388.59% | −2,729.27% | N/A |
| Basic EPSper basic share | -$1.11 | -$1.21 | -$2.25 | -$20.28 | -$26.40 | -$51.20 | -$89.80 | -$84.20 |
| Diluted EPSper diluted share | -$1.11 | -$1.21 | -$2.25 | -$20.28 | -$26.40 | -$51.20 | -$89.80 | -$84.20 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Fairmount Healthcare Fund II L.P. / Harwin Peter Evan / Kiselak Tomas / Fairmount Funds Management LLC / Fairmount Healthcare Co-Invest VI L.P. | 9.1M |
Shah Nimish P | 4.55M |
Hecht Peter M | 910.31K |
Violin Jonathan | 207.4K |
Graul Regina Margaret | 107.52K |
Higgins Michael J | 30.74K |
CHICKO RHONDA M. | 25.02K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 3 ↗Updated Oct 21, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 21, 2024Form 4 | Greenspan David Gerald +1TenPercentOwner | SellCommon Stock, no par value · indirect | 357.9K | $1.55 | $554.7K | 0 |